GlassScriptPhysician profile
Alberto J Gonzalez
NPI 1487677696
$3,685.99
in general payments reported to CMS, 2019-2025
24 companies · $714 in 2025
The $714 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $157 · 2021: $304 · 2022: $305 · 2023: $430 · 2024: $900 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $869.48 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $723.47 | 2019-2024 | Spravato |
| Abbvie INC. | $450.65 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $256.50 | 2021-2025 | Caplyta |
| Alkermes, INC. | $180.25 | 2019-2024 | Lybalvi, Vivitrol |
| Indivior INC. | $166.44 | 2021-2025 | Perseris, Sublocade |
| Bausch Health US, LLC | $122.38 | 2021-2025 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $119.69 | 2019-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $107.02 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $100.15 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $94.27 | 2019-2024 | |
| Noven Therapeutics, LLC | $80.48 | 2024 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $68.34 | 2019-2021 | |
| Almatica Pharma LLC | $53.94 | 2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $46.25 | 2019-2024 | Fanapt, Hetlioz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $43.08 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $41.37 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $40.61 | 2024 | Ingrezza |
| Allergan, INC. | $37.81 | 2019-2020 | |
| Shire North American Group INC | $19.31 | 2019 | |
| Medtronic, INC. | $16.95 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.35 | 2019 | |
| Janssen Scientific Affairs, LLC | $15.81 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.39 | 2023 | Winlevi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.